Corpus overview


Overview

MeSH Disease

Human Phenotype

Viremia (2)


Transmission

There are no transmission terms in the subcorpus


Seroprevalence
    displaying 1 - 2 records in total 2
    records per page




    SARS-CoV-2 Viral Load is Associated with Increased Disease Severity and Mortality

    Authors: Jesse M Fajnzylber; James Regan; Kendyll Coxen; Heather Corry; Colline Wong; Alexandra Rosenthal; Daniel Worrall; Francoise Giguel; Alicja Piechocka-Trocha; Caroline Atyeo; Stephanie Fischinger; Andrew Chan; Keith T Flaherty; Kathryn Hall; Michael Dougan; Edward T Ryan; Elizabeth Gillespie; Rida Chishti; Yijia Li; Nikolaus Jilg; Dusan Hanidziar; Rebecca M Baron; Lindsey Baden; Athe M Tsibris; Katrina A Armstrong; Daniel R Kuritzkes; Galit Alter; Bruce D Walker; Xu Yu; Jonathan Li; - Massachusetts Consortium for Pathogen Readiness

    doi:10.1101/2020.07.15.20131789 Date: 2020-07-17 Source: medRxiv

    The relationship between SARS-CoV-2 viral load and risk of disease progression remains largely undefined in coronavirus disease 2019 (COVID-19). We quantified SARS-CoV-2 viral load from participants with a diverse range of COVID-19 severity, including those requiring hospitalization, outpatients with mild disease, and individuals with resolved infection. SARS-CoV-2 plasma SERO RNA was detected in 27% of hospitalized participants and 13% of outpatients diagnosed with COVID-19. Amongst the participants hospitalized with COVID-19, higher prevalence SERO of detectable SARS-CoV-2 plasma SERO viral load was associated with worse respiratory disease severity, lower absolute lymphocyte counts, and increased markers of inflammation, including C-reactive protein and IL-6. SARS-CoV-2 viral loads, especially plasma SERO viremia HP, were associated with increased risk of mortality. SARS-CoV-2 viral load may aid in the risk stratification of patients with COVID-19 and its role in disease pathogenesis should be further explored.

    SARS-CoV-2 Viral Load is Associated with Increased Disease Severity and Mortality

    Authors: Jesse Fajnzylber; James Regan; Kendyll Coxen; Heather Corry; Colline Wong; Alexandra Rosenthal; Daniel Worrall; Francoise Giguel; Alicja Piechocka-Trocha; Caroline Atyeo; Stephanie Fischinger; Andrew Chan; Keith Flaherty; Kathryn Hall; Michael Dougan; Edward Ryan; Elizabeth Gillespie; Rida Chishti; Yijia Li; Nikolaus Jilg; Dusan Hanidziar; Rebecca Baron; Lindsey Baden; Athe Tsibris; Katrina Armstrong; Galit Alter; Daniel Kuritzkes; Bruce Walker; Xu Yu; Jonathan Li

    doi:10.21203/rs.3.rs-43878/v1 Date: 2020-07-15 Source: ResearchSquare

    The relationship between SARS-CoV-2 viral load and risk of disease progression remains largely undefined in coronavirus disease MESHD 2019 (COVID-19). We quantified SARS-CoV-2 viral load from participants with a diverse range of COVID-19 severity, including those requiring hospitalization, outpatients with mild disease, and individuals with resolved infection MESHD. SARS-CoV-2 plasma SERO RNA was detected in 27% of hospitalized participants and 13% of outpatients diagnosed with COVID-19. Amongst the participants hospitalized with COVID-19, higher prevalence SERO of detectable SARS-CoV-2 plasma SERO viral load was associated with worse respiratory disease MESHD severity, lower absolute lymphocyte counts, and increased markers of inflammation MESHD, including C-reactive protein and IL-6. SARS-CoV-2 viral loads, especially plasma SERO viremia HP viremia MESHD, were associated with increased risk of mortality. SARS-CoV-2 viral load may aid in the risk stratification of patients with COVID-19 and its role in disease pathogenesis should be further explored.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.